Histamine as a potential adjuvant to immuno and radiotherapy for cancer treatment: Discovering new functions for the oldest biogenic amine

Current Immunology Reviews

Volumn 6, Issue 4, 2010, Pages 357-370

  Medina, Vanina A ^a,b   Rivera, Elena S ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

Author keywords

Cancer treatment; Histamine; Histamine receptors; Immune system; Immunotherapy; Radioprotection

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 4 METHYLHISTAMINE; ALPHA2B INTERFERON; AMINE OXIDASE (COPPER CONTAINING); ANTISENSE OLIGONUCLEOTIDE; CLOZAPINE; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; HISTAMINE METHYLTRANSFERASE; HISTIDINE DECARBOXYLASE; HISTIDINE DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; MONOFLUORMETHYLHISTIDINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGRANULOCYTOSIS; ALLERGIC ASTHMA; ALLERGY; ANTIGEN PRESENTING CELL; ARTICLE; BASOPHIL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 3; CLINICAL TRIAL; COLONY FORMING UNIT C; COLONY FORMING UNIT S; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MEGADOSE; GENE SEQUENCE; HEMATOPOIESIS; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; HYPOTENSION; IMMUNE FUNCTION TEST; IMMUNE SYSTEM; INFLAMMATION; IONIZING RADIATION; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER METASTASIS; LUNG EDEMA; MAST CELL; MELANOMA; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RADIOSENSITIVITY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 78649232365     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/1573395511006040357     Document Type: Article

References (202)

1. Kahlson G, Rosengren E. New approaches to the physiology of histamine. Physiol Rev 1968; 48: 155-96.
2. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997; 49: 253-84.
3. Watanabe T, Timmerman H, Yanai K, Eds. Histamine research in the new millennium. Amsterdam: Elsevier Science 2001.
4. Barger G, Dale HM. The presence in ergot and physiological activity of B. iminazoylethylamine. J Physiol Paris 1910; 40: 38-40.
5. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008; 88(3): 1183-241.
6. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4: 121-30.
7. Zampeli E, Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009; 157: 24-33.
8. Ohtsu H, Tanaka S, Terui T, Watanabe T. Falus A. Mice lacking histidine decarboxilase exhibit abnormal mast cells. FEBS Lett 2001; 502: 53-6.
9. Watanabe T, Nakamura H, Liang LY, Yamatodani A, Wada H. Partial purification and characterization of L-Histidine decarboxilase from fetal rat. Biochem Pharmacol 1979; 28: 1149-55.
10. Falus A. In: Falus A, Ed. Histamine and inflammation. Austin: RG Landes Company. 1994; pp. 33-60.
11. Buffoni F. Histaminase and related amino oxidases. Pharmacol Rev 1966; 18: 1163-99.
12. Schwelberger H. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest, SpringMed Publishing 2004; pp. 43-52.
13. Schwelberger. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest, Hungary: SpringMed Publishing 2004; pp. 53-9.
14. Middleton RJ, Martin SA, Bulfield GA. New regulatory gene in the histidine decarboxylase gene complex determines the responsiveness of the mouse kidney enzyme to testosterone. Genet Res 1987; 49: 61-7.
15. Zahnow CA, Panula P, Yamatodani A, Millhorn DE. Glucocorticoid hormones downregulate histidine decarboxylase mRNA and enzyme activity in rat lung. Am J Physiol 1998; 275: L407-13.
16. Darvas Z, Falus A. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest. SpringMed Publishing 2004; pp. 31-42.
17. Abe Y, Ogino S, Irifune M, Imamura J, Fukui M, Wada H. Histamine content, synthesis and degradation in human nasal mucosa. Clin Exp Allergy 1993; 23: 132-6.
18. Pós Z, Hegyesi H, Rivera ES. In: Falus A, Ed. Histamine: Biology and Medical Aspects. Budapest, SpringMed Publishing 2004; pp. 199-217.
19. Garcia-Caballero M, Brandes L, Hosoda S, Eds. Histamine in normal and cancer cell proliferation. Advances in Bioscience 89. Oxford: Pergamon Press 1993.
20. Rivera E, Cricco G, Engel N, Fitzsimons C, Martin G, Bergoc R. Histamine as an autocrine growth factor: an unusual role for a widespread mediator. Semin Cancer Biol 2000; 10: 15-23.
21. Ash AS, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol Chemother 1966; 27: 427-39.
22. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2-receptors. Nature 1972; 236: 385-90.
23. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-7.
24. Lovenberg TW, Roland BI, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999; 55: 1101-7.
25. Yamashita M, Fukui H, Sugama K, et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci U S A 1991; 88: 11515-9.
26. Gantz I, Munzert G, Tashiro T, et al. Molecular cloning of the human histamine H2 receptor. Biochem Biophys Res Commun 1991; 178: 1386-92.
27. Gantz I, Schäffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci USA 1991; 88: 429-33.
28. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000; 279: 615-20.
29. Nguyen T, Shapiro DA, George SR, et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001; 59: 427-33.
30. Liu C, MA XJ, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol Pharmacol 2001; 59: 420-6.
31. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J Biol Chem 2000; 275: 36781-6.
32. Zhu Y, Michalovich D, Wu H, et al. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 2001; 59: 434-41.
33. Morse KL, Behan J, Laz TM, et al. Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther 2001; 296: 1058-66.
34. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-98.
35. Akdis CA, Simons FER. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol 2006; 533: 69-76.
36. van Rijn RM, Chazot PL, Shenton FC, Sansuk K, Bakker RA, Leurs R. Oligomerization of recombinant and endogenously expressed human histamine H(4) receptors. Mol Pharmacol 2006; 70: 604-15.
37. Fukushima Y, Asano T, Saitoh T, et al. Oligomer formation of histamine H2 receptors expressed in Sf9 and COS7 cells. FEBS Lett 1997; 409: 283-6.
38. Bongers G, Bakker RA, Leurs R. Molecular aspects of histamine H3 receptor. Biochem Pharmacol 2007; 73: 1195-204.
39. Bakker RA, Dees G, Carrillo JJ, et al. Domain swapping in the human histamine H1 receptor. J Pharmacol Exp Ther 2004; 311: 131-8.
40. Jablonowski JA, Grice CA, Chai W, et al. The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 2003; 46: 3957-60.
41. Leurs R, Chazot PL, Shenton FC, Lim HD, de Esch IJ. Molecular and biochemical pharmacology of the histamine H4 receptor. Br J Pharmacol 2009; 157: 14-23.
42. Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C, Arrang JM. Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol 2006; 147: 744-54.
43. Igaz P, Hegyesi H. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest: SpringMed Publishing 2004; pp. 69-77.
44. Bakker RA, Schoonus SBJ, Smit MJ, Timmerman H, Leurs R. Histamine H1-receptor activation of nuclear factor-κB; roles for G gamma-and G alpha/11 subunits in constitutive and agonistmediated signaling. Mol Pharmacol 2001; 60: 1133-42.
45. Dy M, Schneider E. Histamine-cytokine connection in immunity and hematopoiesis. Cytokine Growth Factor Rev 2004; 15: 393-410.
46. Schneider E, Rolli-Derkinderen M, Arock M, Dy M. Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol 2002; 23: 255-63.
47. Lázár-Molnár E. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest: SpringMed Publishing 2004; pp. 89-96.
48. Davio CA, Cricco GP, Bergoc RM, Rivera ES. H1 and H2 histamine receptors in experimental carcinomas with an atypical coupling to signal transducers. Biochem Pharmacol 1995; 50: 91-6.
49. Leurs R, Smits MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995; 66: 413-63.
50. Smit MJ, Hoffmann M, Timmerman H, Leurs R. Molecular properties and signaling pathways of the histamine H1 receptor. Clin Exp Allergy 1999; 29: 19-28.
51. Fitzsimons C, Engel N, Policastro L, Durán H, Molinari B, Rivera E. Regulation of phospholipase C activation by the number of H(2) receptors during Ca(2+)-induced differentiation of mouse keratinocytes. Biochem Pharmacol 2002; 63: 1785-96.
52. Mitsuhashi M, Mitsuhashi T, Payan D. Multiple signaling pathways of histamine H2 receptors. Identification of an H2 receptor-dependent Ca2+ mobilization pathway in human HL-60 promyelocytic leukemia cells. J Biol Chem 1989; 264: 18356-62.
53. Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC, Arrang JM. Chromosomal mapping and organization of the human histamine H3 receptor gene. Neuroreport 2001; 12: 321-4.
54. Coge F, Guenin SP, Audinot V, et al. Genomic organization and characterization of splice variants of the human histamine H3 receptor. Biochem J 2001; 355: 279-88.
55. Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM. Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacol 2002; 42: 929-40.
56. Leurs R, Bakker RA, Timmerman H, de Esch IJP. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev 2005; 4: 107-22.
57. Bakker RA. Histamine H3 receptor isoforms. Inflamm Res 2004; 53: 509-16.
58. Bakker RA, Lozada AF, Van Marle A, et al. Discovery of naturally occurring splice variants of the rat histamine H3 receptor that act as dominant-negative isoforms. Mol Pharmacol 2006; 69: 1194-206.
59. Hancock AA, Esbenshade TA, Krueger KM, Yao BB. Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003; 73: 3043-72.
60. Hancock AA. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists. Biochem Pharmacol 2006; 71: 1103-13.
61. Krueger KM, Witte DG, Ireland-Denny L, et al. G proteindependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther 2005; 314: 271-81.
62. Cherifi I, Pigeon C, Le romancer M, Bado A, Reyl-Desmars F, Lewin MJM. Purification of a histamine H3 receptor negatively coupled to phosphoinositide turnover in the human gastric cell line HGT1. J Biol Chem 1992; 267: 25315-20.
63. Huang JF, Thurmond RL. The new biology of histamine receptors. Curr Allergy Asthma Rep 2008; 8: 21-7.
64. Sander LE, Lorentz A, Sellge G, et al. Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut 2006; 55: 498-504.
65. Connelly WM, Shenton FC, Lethbridge N, et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 2009; 157: 55-63.
66. Breunig E, Michel K, Zeller F, Seidl S, Weyhern CW, Schemann M. Histamine excites neurons in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol 2007; 583: 731-42.
67. Medina V, Cricco G, Nuñez M, et al. Histamine-mediated signaling processes in human malignant mammary cells. Cancer Biol Ther 2006; 5: 1462-71.
68. Medina V, Croci M, Crescenti E, et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 2008; 7: 28-35.
69. Cianchi F, Cortesini C, Schiavone N, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res 2005; 11: 6807-15.
70. Tiligada E, Zampeli E, Sander K, Stark H. Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 2009; 18: 1519-31.
71. De Esch JP, Thurmond RL, Jongejan A, Leurs R. The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 2005; 26: 462-9.
72. Coge F, Guenin SP, Rique H, Boutin JA, Galizzi JP. Structure and expression of the human histamine H4-receptor gene. Biochem Biophy Res Commun 2001; 284: 301-9.
73. van Rijn RM, van Marle A, Chazot PL, et al. Cloning and characterization of dominant negative splice variants of the human histamine H4 receptor. Biochem J 2008; 414: 121-31.
74. Bartholeyns J, Fozard J. Role of histamine in tumor development. Trends Pharmacol Sci 1985: 6: 123-25.
75. Engel N, Cricco G, Davio C, et al. Histamine regulates the expression of histidine decarboxylase in NMU-induced tumors in rats. Inflamm Res 1996; 45: 64-5.
76. Hegyesi H, Somalí B, Varga VL, et al. Suppression of melanoma cell proliferation by histidine decarbolxylase specific antisense oligonucleotides. J Investigative Dermatol 2001; 117: 151-3.
77. Reynolds JL, Akhter J, Adams WJ, Morris DL. Histamine content in colorectal cancer. Are there sufficient levels of histamine to affect lymphocyte function? Eur J Surg Oncol 1997; 23: 224-7.
78. Sieja K, Stanosz S, Von Mach-Szczypinski J, Olewniezak S, Stanosz M. Concentration of histamine in serum and tissues of the primary ductal breast cancer in women. Breast 2005; 14: 236-41.
79. Garcia-Caballero M, Neugebauer E, Campos R, Nuñez de Castro I, Vara-Thorbeck C. Histamine synthesis and content in benign and malignant breast tumors. Surg Oncol 1994; 3: 167-73.
80. Kierska D, Fogel W, Malinski C. Histamine concentration and metabolism in mouse mammary gland during strous cycle. Inflamm Res 1997; 46: 63-4.
81. Wagner W, Ichikawa A, Tanaka S, Panula P, Fogel WA. Mouse mammary epithelial histamine system. J Physiol Pharm 2003; 54: 211-23.
82. Wang LD, Hoeltzel M, Butler B, et al. Activation of the human histamine H2 receptor is linked to cell proliferation and c-fos gene transcription. Am J Physiol 1997; 273: C2037-45.
83. Davenas E, Rouleau A, Morisset S, Arrang JM. Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors. J Pharmacol Exp Ther 2008; 326: 406-13.
84. Bartholeyns J, Bouclier M. Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluormethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarbolxylase. Cancer Res 1984; 44: 639-45.
85. Pós Z, Sáfrány G, Müller K, Tóth S, Falus A, Hegyesi H. Phenotypic profiling of engineered mouse melanomas with manipulated histamine production identifies histamine H2 receptor and Rho-c as histamine-regulated melanoma progression markers. Cancer Res 2005; 65: 4458-66.
86. Kitamura Y, Das AK, Murata Y, et al. Dexamethasone suppresses histamine synthesis by repressing both transcription and activity of HDC in allergic rats. Allergol Int 2006; 55: 279-86.
87. Ohgoh M, Yamamoto J, Kawata M, Yamamura I, Fukui T, Ichikawa A. Enhanced expression of the mouse L-histidine decarboxylase gene with a combination of dexamethasone and 12-O-tetradecanoylphorbol-13-acetate. Biochem Biophys Res Commun 1993; 196: 1113-9.
88. Igaz P, Falus A. In: Falus A, Ed. Histamine: Biology and Medical Aspects. Budapest, SpringMed Publishing 2004; pp. 112-7.
89. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003; 112: 15-22.
90. Marone G, Granata F, Spadaro G, Genovese A, Triggiani M. The histamine-cytokine network in allergic inflammation. J Allergy Clin Immunol 2003; 112: S83-8.
91. Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA. Immune regulation by histamine. Curr Opin Immunol 2002; 14: 735-40.
92. Watt AP, Ennis M. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest, SpringMed Publishing 2004; pp. 99-111.
93. Xie H, He SH. Roles of histamine and its receptors in allergic and inflammatory bowel diseases. World J Gastroenterol 2005; 11: 2851-7.
94. Banu Y, Watanabe T. Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling. J Exp Med 1999; 189: 673-82.
95. Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413: 420-4.
96. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy 2006; 91: 174-87.
97. Jutel M, Klunker S, Akdis M, et al. Histamine upregulates Th1 and downregulates Th2 responses due to different patterns of surface histamine 1 and 2 receptor expression. Int Arch Allergy Immunol 2001; 124: 190-2.
98. Gantner F, Sakai K, Tusche MW, Cruikshank WW, Center DM, Bacon KB. Histamine H(4) and H(2) receptors control histamineinduced interleukin-16 release from human CD8(+) T cells. J Pharmacol Exp Ther 2002; 303: 300-7.
99. O'Reilly M, Alpert R, Jenkinson S, et al. Identification of a histamine H4 receptor on human eosinophils -role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002; 22: 431-48.
100. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther 2003; 305: 1212-21.
101. Jutel M, Blaser K, Akdis CA. Histamine in chronic allergic responses. J Investig Allergol Clin Immunol 2005; 15: 1-8.
102. Jutel M, Blaser K, Akdis CA. Histamine receptors in immune regulation and allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006; 26: 245-59.
103. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL. The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. J Immunol 2006: 176: 7062-70.
104. Gutzmer R, Diestel C, Mommert S, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol 2005; 174: 5224-32.
105. Dy M, Schneider E, Gastinel LN, Auffray C, Mermod JJ, Hamburger J. Histamine-producing cell-stimulating activity. A biological activity shared by interleukin 3 and granulocytemacrophage colony stimulating factor. Eur J Immunol 1987; 17: 1243-8.
106. Schneider E, Pollard H, Lepault F, Guy-Grand D, Minkowski M, Dy M. Histamine-producing cell-stimulating activity: interleukin 3 and granulocyte-macrophage colony-stimulating factor induce de novo synthesis of histidine decarboylase in hemopoietic progenitor cells. J Immunol 1987; 139: 3710-7.
107. Yamaguchi K, Motegi K, Endo Y. Induction of histidine decarboxylase, the histamine-forming enzyme, in mice by interleukin-12. Toxicology 2000; 156: 57-65.
108. Yamaguchi K, Motegi K, Kurimoto M, Endo Y. Induction of the activity of the histamine-forming enzyme, histidine decarboxylase, in mice by IL-18 and by IL-18 plus IL-12. Inflamm Res 2000; 49: 513-9.
109. Schneider E, Lemoine F, Breton-Gorius J, et al. IL-3-induced coexpression of IL-4, IL-6 and histidine decarboxylase mRNA in basophilic myelocytes enriched in sorted-Rh-bright bone marrow cells. Exp Haematol 1999; 27: 1010-8.
110. Abbas AK, Lichtman AH, Pober JS, Eds. Cellular and molecular immunology. Philadelphia: WB Saunders Company 2000.
111. Szeberényi JB, Pállinger E, Zsinkó M, et al. Inhibition of effects of endogenously synthesized histamine disturbs in vitro human dendritic cell differentiation. Immunol Lett 2001; 76: 175-82.
112. Idzdo M, La Sala A, Ferrari D, et al. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002; 109: 839-46.
113. Caron G, Delneste Y, Roelandts E, et al. Histamine induces CD86 expression and chemokine production by human immature dendritic cells. J Immunol 2001; 166: 6000-6.
114. Gutzmer R, Langer K, Lisewski M, et al. Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002; 109: 524-31.
115. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108: 1865-73.
116. van der Pouw Kraan TC, Snijders A, Boeije LC, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998; 102: 1866-73.
117. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998; 161: 2586-93.
118. Takahashi HK, Iwagaki H, Mori S, Yoshino T, Tanaka N, Nishibori M. Histamine inhibits lipopolysaccharide-induced interleukin (IL)-18 production in human monocytes. Clin Immunol 2004; 112: 30-4.
119. Vannier E, Dinarello CA. Histamine enhances interleukin (IL)-1-induced IL-1 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. Comparison with IL-1 receptor antagonist. J Clin Invest 1993; 92: 281-7.
120. Morichika T, Takahashi HK, Iwagaki H, et al. Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1-and B7.1-dependent manner. J Pharmacol Exp Ther 2003; 304: 624-33.
121. Mazzoni A, Leifer CA, Mullen GED, Kennedy MN, Klinman DM, Segal DM. Cutting edge: histamine inhibits IFN-a release from plasmacytoid dendritic cells. J Immunol 2003; 170: 2269-73.
122. Ohtani T, Aiba S, Mizuashi M, Mollah ZU, Nakagawa S, Tagami H. H1 and H2 histamine receptors are absent on Langerhans cells and present on dermal dendritic cells. J Invest Dermatol 2003; 121: 1073-9.
123. Dijkstra D, Leurs R, Chazot P, et al. Histamine downregulates monocytes CCL2 production through the histamine H4 receptor. J Allergy Clin Immunol 2007; 120: 300-7.
124. Dijkstra D, Stark H, Chazot PL, et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol 2008; 128: 1696-703.
125. Maghazachi AA, Al-Aoukaty A. Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer. FASEB J 1998; 12: 913-24.
126. Damaj BB, Barrena Becerra C, Esber HJ, Wen Y, Maghazachi AA. Functional Expression of H4 Histamine Receptor in Human Natural Killer Cells, Monocytes, and Dendritic Cells. J Immunol 2007; 179: 7907-15.
127. Byron JW. Mechanism for histamine H2-receptor induced cellcycle changes in the bone marrow stem cell. Agents Actions 1977; 7: 209-13.
128. Nakaya N, Tasaka K. The influence of histamine on precursor of granulocytic leukocytes in murine bone marrow. Life Sci 1999; 42: 999-1010.
129. Scheneider E, Dy M. In: Falus A, Ed. Histamine: biology and medical aspects. Budapest, SpringMed Publishing 2004; pp. 226-39.
130. Schneider E, Piquet-Pellorce C, Dy M. New role for histamine in interleukin-3 induced proliferation of hematopoietic stem cells. J Cell Physiol 1990; 143: 337-43.
131. Piquet-Pellorce C, Schneider E, Dy M. GM-CSF in association with IL-1 triggers day-8 CFU-S into cell cycle: role of histamine. J Cell Physiol 1991; 149:18.
132. Ohtsu H, Tanaka S, Terui T, et al. Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 2001; 502: 53-6.
133. Horvath Z, Pallinger E, Horvath G, Jelinek I, Falus A, Buzas EI. Histamine H1 and H2 receptors but not H4 receptors are upregulated during bone marrow regeneration. Cell Immunol 2006; 244: 110-5.
134. Wiener Z, Andrásfalvy M, Pállinger E, et al. Bone marrow-derived mast cell differentiation is strongly reduced in histidine decarboxylase knockout, histamine-free mice. Int Immunol 2002; 14: 381-7.
135. Aglietta M, Stacchini A, Sanavio F, Piacibello W. H2 receptor antagonists and human granulopoiesis. Experientia 1985; 41: 375-6.
136. Fitchen JH, Koeffler HP. Cimetidine and granulopoiesis: bone marrow culture studies in normal man and patients with cimetidineassociated neutropenia. Br J Haematol 1980; 46: 361-6.
137. Byron JW. Pharmacodynamic basis for the interaction of cimetidine with the bone marrow stem cells (CFUS). Exp Hematol 1980; 8: 256-63.
138. Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 1988; 3: 430-48.
139. Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 2008; 9: 1101-11.
140. Ghaznavi S, Nakic M, Rao P, et al. Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry 2008; 165: 813-8.
141. Petit-Bertron AF, Machavoine F, Defresne MP, et al. H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cells. PLoS One 2009; 4:e6504.
142. Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008; 94: 67-82.
143. Thurmond RL, Desai PJ, Dunford PJ, et al. A Potent and Selective Histamine H4 Receptor Antagonist with Anti-Inflammatory Properties. JPET 2004; 309: 404-13.
144. Herjavecz I, Hirschberg A. In: Falus A Ed. Histamine: Biology and Medical Aspects. Budapest, SpringMed Publishing 2004; 140-58.
145. Bayram H, Devalia JL, Khair OA, et al. Effect of loratadine on nitrogen dioxide-induced changes in electrical resistance and release of inflammatory mediators from cultured human bronchial epithelial cells. J Allergy Clin Immunol 1999; 104: 93-9.
146. Jeannin P, Delneste Y, Gosset P, et al. Histamine induces interleukin-8 secretion by endothelial cells. Blood 1994; 84: 2229-33.
147. Meretey K, Falus A, Taga T, Kishimoto T. Histamine influences the expression of the interleukin-6 receptor on human lymphoid, monocytoid and hepatoma cell lines. Agents Actions 1991; 33: 189-91.
148. Igaz P, Novák I, Lázaár E, Horváth B, Héninger E, Falus A. Bidirectional communication between histamine and cytokines. Inflamm Res 2001; 50: 123-8.
149. Fujikura T, Shimosawa T, Yakuo I. Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa. J Allergy Clin Immnol 2001; 107: 123-8.
150. Katoh N, Soga F, Nara T, Masuda K, Kishimoto S. Histamine induces the generation of monocyte-derived dendritic cells that express CD14 but not CD1a. J Invest Dermatol 2005; 125: 753-60.
151. Kubes P, Kanwar S. Histamine induces leukocyte rolling in postcapillary venules. A P-selectin-mediated event. J Immunol 1994; 152: 3570-7.
152. Yamaki K, Thorlacius H, Xie X, Lindbom L, Hedqvist P, Raud J. Characteristics of histamine-induced leukocyte rolling in the undisturbed microcirculation of the rat mesentery. Br J Pharmacol 1998; 123: 390-9.
153. Schaefer U, Schmitz V, Schneider A, Neugebauer E. Histamine induced homologous and heterologous regulation of histamine receptor subtype mRNA expression in cultured endothelial cells. Shock 1999; 12: 309-15.
154. Clark RA, Sandler JA, Gallin JI, Kaplan AP. Histamine modulation of eosinophil migration. J Immunol 1977; 118: 137-45.
155. Seligmann BE, Fletcher MP, Gallin JI. Histamine modulation of human neutrophil oxidative metabolism, locomotion, degranulation, and membrane potential changes. J Immunol 1983; 130: 1902-9.
156. Hirasawa N, Ohtsu H, Watanabe T, Ohuchi K. Enhancement of neutrophil infiltration in histidine decarboxylase-deficient mice. Immunology 2002; 107: 217-21.
157. Jutel M, Blaser K, Akdis CA. Histamine in allergic inflammation and immune modulation. Int Arch Allergy Immunol 2005; 137: 82-92.
158. Packard KA, Khan MM. Effects of histamine on Th1/Th2 cytokine balance. Int Immunopharmacol 2003; 3: 909-20.
159. Brightling CE, Bradding P. The re-emergence of the mast cell as a pivotal cell in asthma pathogenesis. Curr Allergy Asthma Rep 2005; 5: 130-5.
160. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008; 7:41-53.
161. Bäumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin-immunomodulatory role of histamine. Allergy 2008; 63: 1387-94.
162. Buckland KF, Williams TJ, Conroy DM. Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br J Pharmacol 2003; 140:1117-27.
163. Ling P, Ngo K, Nguyen S, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol 2004; 142: 161-71.
164. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher P. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001; 90: 105-56.
165. Mitchell MS. Immunotherapy as part of combinations for the treatment of cancer. Int Immunopharmacol 2003; 3: 1051-9.
166. Stadtmauer EA. Histamine dihydrochloride and interleukin-2 in the treatment of acute myeloid leukemia. Semin Oncol 2002; 29: 47-51.
167. Hellstrand K. Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 2002; 29: 35-40.
168. Galmarini CM. Histamine dihydrochloride (subcutaneous) Maxim. Curr Opin Investig Drugs 2004; 5: 1298-310.
169. Perz JB, Ho AD. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. Future Oncol 2008; 4: 169-77.
170. Agarwala SS, Sabbagh MH. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment. Expert Opin Biol Ther 2001; 1: 869-79
171. Naredi P. Histamine as an adjunct to immunotherapy. Semin Oncol 2002; 29: 31-4.
172. Hellstrand K, Hansson M, Hermodsson S. Adjuvant histamine in cancer immunotherapy. Semin Cancer Biol 2000; 10: 29-39.
173. Romero AI, Thoren FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009; 70: 194-205.
174. Hellstrand K, Brune M, Dahlgren C, et al. Alleviating oxidative stress in cancer immunotherapy: a role for histamine? Med Oncol 2000; 17: 258-69.
175. Agarwala SS, Hellstrand K, Gehlsen K, Naredi P. Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother 2004; 53: 840-1.
176. Asemissen AM, Scheibenbogen C, Letsch A, et al. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Clin Cancer Res 2005; 11: 290-7.
177. O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res 2003; 13: 307-11.
178. Middleton M, Hauschild A, Thomson D, et al. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride vs dacarbazine in patients with stage IV melanoma. Ann Oncol 2007; 18: 1691-7.
179. Thorén FB, Romero AI, Brune M, Hellstrand K. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opin Biol Ther 2009; 9: 1217-23.
180. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006; 108: 88-96.
181. Donskov F, Hokland M, Marcussen N, Torp Madsen HH, von der Maase H. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma-results from a randomised phase II trial. Br J Cancer 2006; 94: 218-26.
182. Donskov F, Middleton M, Fode K, et al. Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 2005; 93: 757-62.
183. Donskov F, von der Maase H, Henriksson R, et al. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open singlearmed multicentre phase II study. Ann Oncol 2002; 13: 441-9.
184. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment tumorigenesis and therapy. Nature 2005; 5: 867-74.
185. Grdina DJ, Murley JS, Kataoka Y. Radioprotectans: current status and new directions. Oncology 2002; 63: 2-10.
186. Hall EJ, Giaccia AJ. In: Hall EJ, Giaccia AJ, Eds. Radiobiology for radiobiologists. Philadelphia: Lippincott Williams and Wilkins 2006; pp. 129-34.
187. Dziegielewski J, Baulch JE, Goetz W, et al. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability. Free Radic Biol Med 2008; 45: 1674-81.
188. Weichselbaum R. Radiation's outer limits. Nat Med 2005; 11: 477-8.
189. Hall EJ, Giaccia. In: Hall EJ, Giaccia AJ, Eds. Radiobiology for radiobiologists. Philadelphia: Lippincott Williams and Wilkins 2006; pp. 303-326.
190. Betzen SM, Overgaard J. In: Steel GG, Ed. Basic Clinical Radiobiology. New York: Oxford University press, Inc. 1997; pp. 87-97.
191. Hall EJ, Giaccia AJ. In: Hall EJ, Giaccia AJ, Eds. Radiobiology for radiobiologists. Philadelphia: Lippincott Williams and Wilkins 2006; 327-48.
192. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-22.
193. Medina V, Croci M, Mohamad N, et al. Mechanisms underlying the radioprotective effect of histamine on small intestine. Int J Radiat Biol 2007; 83: 653-63.
194. Potten CS, Wilson JW, Booth C. Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. Stem Cells 1997; 15: 82-93.
195. Potten CS. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. Philos Trans R Soc Lond B Biol Sci 1998; 353: 821-30.
196. Potten CS, Owen G, Booth D. Intestinal stem cells protect their genome by selective segregation of template DNA strands. J Cell Sci 2002; 115: 2381-8.
197. Medina V, Croci C, Carabajal E, Bergoc RM, Rivera ES. Histamine protects bone marrow against cellular damage induced by ionizing radiation. Int J Radiat Biol 2010; 86: 283-90.
198. Nagler RM. The enigmatic mechanism of irradiation-induced damage to the major salivary glands. Oral Dis 2002; 8: 141-6.
199. Valdez IH, Atkinson JC, Ship JA, et al. Major salivary gland function in patients with radiation-induced xerostomia: flow rates and sialochemistry. Int J Radiat Oncol Biol Phys 1993; 25: 41-7.
200. Vissink A, Jansma J, Spijkervet FKL, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14: 199-212.
201. Burlage FR, Coppes RP, Meertens H, et al. Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiother Oncol 2001; 31: 271-3.
202. Burlage FR, Roesink JM, Kampinga HH, et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. Int J Radiat Oncol Biol Phys 2008; 70: 14-22.